Edition:
United States

China Biologic Products Holdings Inc (CBPO.OQ)

CBPO.OQ on NASDAQ Stock Exchange Global Select Market

81.53USD
21 Sep 2018
Change (% chg)

$-0.47 (-0.57%)
Prev Close
$82.00
Open
$82.66
Day's High
$82.66
Day's Low
$81.47
Volume
133,565
Avg. Vol
147,358
52-wk High
$107.32
52-wk Low
$71.87

Latest Key Developments (Source: Significant Developments)

China Biologic Announces Updates On Unsolicited Acquisition Proposals And Strategic Private Placement
Friday, 24 Aug 2018 08:00am EDT 

Aug 24 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES UPDATES ON UNSOLICITED ACQUISITION PROPOSALS AND STRATEGIC PRIVATE PLACEMENT.CHINA BIOLOGIC PRODUCTS - ENTERED AGREEMENTS FOR ISSUANCE & SALE OF 5.9 MILLION SHARES, EXPECTED TO RAISE GROSS PROCEEDS OF ABOUT $590 MILLION.CHINA BIOLOGIC PRODUCTS HOLDINGS - BOARD UNANIMOUSLY DECIDED TO REJECT PREVIOUSLY ANNOUNCED PRELIMINARY NON-BINDING PROPOSAL DATED AUGUST 17.CHINA BIOLOGIC - BOARD RECEIVED LETTER FROM CITIC CAPITAL MB INVESTMENT LIMITED WITHDRAWING ITS PROPOSAL DATED JUNE 11 WITH IMMEDIATE EFFECT.CHINA BIOLOGIC - BOARD FORMED SPECIAL COMMITTEE TO NEGOTIATE, EVALUATE SHARE PURCHASE AGREEMENTS, TRANSACTIONS CONTEMPLATED THEREBY.CHINA BIOLOGIC - CENTURIUM, CITIC, HILLHOUSE, PW MEDTECH TO BUY 3.1 MILLION, 1 MILLION, 1 MILLION, 800,000, NEWLY ISSUED SHARES AT $100.90/SHARE.CHINA BIOLOGIC - UPON RECOMMENDATION OF SPECIAL COMMITTEE UNANIMOUSLY APPROVED SHARE PURCHASE AGREEMENTS AND TRANSACTIONS CONTEMPLATED THEREBY.CHINA BIOLOGIC - ON CLOSING, CENTURIUM, CITIC, HILLHOUSE, PWM TO BENEFICIALLY OWN ABOUT 7.76 PERCENT, 6.82 PERCENT, 6.63 PERCENT, 16.08 PERCENT OF CO'S TOTAL SHARES.  Full Article

Investor Group Proposes To Buy China Biologic Products For $118.00/Share
Monday, 20 Aug 2018 08:30am EDT 

Aug 20 (Reuters) - China Biologic Products Holdings Inc ::LEADING INVESTOR GROUP PROPOSES TO ACQUIRE CHINA BIOLOGIC PRODUCTS FOR US$118.00 PER SHARE IN CASH.CHINA BIOLOGIC PRODUCTS INVESTOR GROUP - INTEND TO FINANCE OFFER TO BUY CHINA BIOLOGIC WITH DEBT & EQUITY CAPITAL .CHINA BIOLOGIC PRODUCTS INVESTOR GROUP - ALL-CASH OFFER VALUED AT APPROXIMATELY $3.9 BILLION.CHINA BIOLOGIC PRODUCTS INVESTOR GROUP - RECEIVED LETTER FROM GOLDMAN SACHS INDICATING ABILITY TO FULLY UNDERWRITE CREDIT FACILITY FOR DEAL AS SOLE LEAD ARRANGER.CHINA BIOLOGIC PRODUCTS INVESTOR GROUP - PROPOSAL WAS CONVEYED ON AUG 17 IN LETTER TO CHINA BIOLOGIC'S BOARD.  Full Article

China Biologic Names Bing Li As New CEO
Monday, 13 Aug 2018 08:00am EDT 

Aug 13 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC NAMES BING LI AS NEW CEO.CHINA BIOLOGIC PRODUCTS HOLDINGS - ZHIJUN TONG, FORMER ACTING CEO, WILL CONTINUE TO SERVE AS AN EXECUTIVE DIRECTOR OF BOARD AND PRESIDENT OF COMPANY.  Full Article

China Biologic Says Its Board Is Evaluating Citic's Proposal
Tuesday, 19 Jun 2018 08:00am EDT 

June 19 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES RECEIPT OF NON-BINDING ACQUISITION PROPOSAL.CHINA BIOLOGIC PRODUCTS - CITIC PROPOSES TO ACQUIRE ALL OF OUTSTANDING SHARES OF COMPANY NOT ALREADY OWNED BY CITIC FOR US$110 IN CASH PER SHARE.CHINA BIOLOGIC PRODUCTS - BOARD IS REVIEWING & EVALUATING CITIC'S PROPOSAL & NO DECISIONS HAVE BEEN MADE WITH RESPECT TO CO'S RESPONSE TO THE PROPOSAL.  Full Article

China Biologic Reports Q4 Adjusted Non-GAAP Earnings Per Share $0.90
Wednesday, 28 Feb 2018 05:00pm EST 

Feb 28 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2017.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.90.Q4 LOSS PER SHARE $0.86.‍TOTAL SALES IN Q4 OF 2017 INCREASED BY 12.2% IN RMB TERMS AND 16.1% IN USD TERMS TO $90.1 MILLION.‍FOR FULL YEAR OF 2018, COMPANY EXPECTS TOTAL SALES TO GROW 18% TO 20% IN RMB TERMS​.‍FOR FULL YEAR OF 2018, EXPECTS NON-GAAP ADJUSTED NET INCOME TO GROW 16% TO 18% IN RMB TERMS.‍EXCLUDING TIANXINFU CONTRIBUTION, ESTIMATED SALES FOR 2018 ARE EXPECTED TO GROW 6% TO 8% IN RMB TERMS​.CHINA BIOLOGIC PRODUCTS HOLDINGS - ‍ EXCLUDING TIANXINFU CONTRIBUTION, FY 2018 NON-GAAP ADJUSTED NET INCOME IS EXPECTED TO GROW 3% TO 4% IN RMB TERMS​.  Full Article

China Biologic To Build New Collection Station In Hainan Province
Wednesday, 14 Feb 2018 08:30am EST 

Feb 14 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC TO BUILD NEW COLLECTION STATION IN HAINAN PROVINCE.CHINA BIOLOGIC PRODUCTS HOLDINGS - CAPEX FOR NEW STATION IN WENCHANG EXPECTED TO BE ABOUT US$3.2 MILLION TO $4.7 MILLION.CHINA BIOLOGIC PRODUCTS - CO'S UNIT RECEIVED APPROVAL FROM HAINAN PROVINCIAL HEALTH & FAMILY PLANNING COMMISSION TO BUILD NEW PLASMA COLLECTION STATION.CHINA BIOLOGIC PRODUCTS HOLDINGS - EXPECTS TO COMMENCE COMMERCIAL OPERATIONS OF NEW STATION, BEFORE END OF 2018.  Full Article

China Biologic Sees FY 2017 Sales Up About 10.5 Pct
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES CORPORATE UPDATE.SEES FY 2017 SALES UP ABOUT 10.5 PERCENT.  Full Article

China Biologic posts Q3 adj. earnings per share $1.38
Wednesday, 1 Nov 2017 04:30pm EDT 

Nov 1 (Reuters) - China Biologic Products Holdings Inc :China Biologic reports unaudited financial results for the third quarter of 2017.Q3 adjusted non-GAAP earnings per share $1.38.Q3 earnings per share $1.11.Q3 sales rose 15.1 percent to $99.6 million.China Biologic Products Holdings Inc - ‍reiterates full year non-GAAP adjusted net income forecast​.China Biologic Products Holdings - ‍adjusting FY 2017 forecast of total sales growth to 9 pct-10 pct in RMB terms compared to previous estimates of 13 pct-15 pct​.  Full Article

China Biologic agrees to acquire Tianxinfu from PWM
Thursday, 12 Oct 2017 08:30am EDT 

Oct 12 (Reuters) - China Biologic Products Holdings Inc :China Biologic agrees to acquire Tianxinfu from PWM.China Biologic Products Holdings Inc - ‍It has agreed to acquire 80% equity interest in Tianxinfu (Beijing) Medical Appliance Co., Ltd​.China Biologic Products - ‍In exchange for acquisition of 80% equity interest in Tianxinfu from PWM, Cbpo will issue 5.5 million ordinary shares to PWM​.China Biologic Products - ‍PWM is expected to hold approximately 16.66% of outstanding share capital of Cbpo taking into effect new issuance​ post deal.China Biologic Products - Board determined to exempt deal from causing PWM to be deemed "acquiring person" under CBPO's preferred shares rights agreement​.China Biologic Products Holdings Inc - ‍Acquire 80% equity interest in Tianxinfu from PW Medtech Group Limited​.China Biologic Products - ‍CBPO elected to be exempted from shareholder approval requirement under applicable rules of nasdaq market for proposed deal.China Biologic Products Holdings - ‍Elected to be exempted from shareholder approval requirement under applicable rules of Nasdaq stock market for deal.China Biologic Products Holdings Inc - ‍Post deal close, PWM expected to hold about 16.66% of share capital of co taking into effect new issuance​.  Full Article

China Biologic receives approval for commercial manufacturing of human fibrinogen
Monday, 9 Oct 2017 08:30am EDT 

Oct 9 (Reuters) - China Biologic Products Holdings Inc :China Biologic receives approval for commercial manufacturing of human fibrinogen.China Biologic Products Holdings Inc - ‍expects first batch of products to be released to market by end of 2017​.China Biologic Products Holdings Inc - ‍expect to see meaningful profit contribution from fibrinogen in 2018​.China Biologic Products Holdings - unit received approval from China food and drug administration for commercial manufacturing of human fibrinogen.  Full Article

China Biologic rejects $3.9 billion bid from former CEO

China Biologic Products Holdings Inc rejected a $3.9 billion offer from a consortium led by its former chief executive on Friday and said an affiliate of CITIC Capital had also withdrawn a competing bid.